Insights
About
About

Startup News: Acquired companies, a look back for 2023

An initial public offering may be the desired outcome for the founders of many private companies. But in a stock market that hasn’t been particularly kind in the past year to a few startups that have made public debuts, a well-priced exit via acquisition could be more appealing to investors.

The past year saw corporate acquisitions of startups such as video-gaming company Scopely, video-messaging service Loom, medical-device maker Relievant Medsystems, B2B intelligence leader Clearbit, and analytics platform Heap.

Video-gaming company Scopely

In April, Scopely agreed to be purchased by Savvy Games Group for $4.9 billion. In a press release announcing the acquisition, Savvy Games, which is wholly owned by Saudi Arabia’s public investment fund, cited Scopely’s track record of developing and publishing a wide range of successful video games, particularly on mobile apps. Scopely created gaming franchises such as “Star Trek,” “Fleet Command,” “Stumble Guys,” and “Scrabble.”

Under the terms of the agreement, Los Angeles-based Scopely has continued to run as an autonomous operating company side by side with other Savvy brands. Founded in 2011, Los Angeles-based Scopely reportedly had a $3.3 billion valuation in October 2020 after it raised $340 billion in a funding round, according to Variety. The publication also reported that Scopely’s valuation rose to $5.4 billion in October 2021 after its acquisition of Sony’s GSM Games unit for $1 billion, so Savvy’s acquisition price represented a modest decline in valuation.

Video-messaging service Loom

In October, Loom, an innovative video messaging platform, agreed to be purchased for $975 million by Atlassian (NASDAQ: TEAM), a leading publicly-traded provider of corporate team collaboration and productivity software. As in the case with Scopely, the purchase price represents a discount from $1.53 billion that San Francisco-based Loom was valued at in May 2021 when it announced a $130 million Series C funding round. Loom has managed to amass more than 25 million users and was honored by Fast Company as one of the world’s 50 most innovative companies in 2023.

Medical-device maker Relievant Medsystems

In September, Minneapolis-based Relievant Medsystems was acquired by medical- device colossus Boston Scientific (NYSE: BSX) for an upfront cash payment of $850 million and additional payments in coming years which are dependent on Relievant’s sales performance, according to a press release announcing the deal. Relievant is primarily known for developing the Intracept nerve ablation system for treating chronic back pain.

B2B intelligence provider Clearbit

Last month, Clearbit, a leading B2B data provider, agreed to be purchased by Hubspot (NYSE: HUBS), a customer relationship management company, for an undisclosed sum. In announcing the deal, Hubspot said that Clearbit will allow it to bring rich third- party company data into its system of record, “making HubSpot the central source of truth for go-to-market professionals.”

Analytics platform Heap

And in September, Heap, a product analytics platform, agreed to be purchased for an undisclosed sum by ContentSquare, a global leader in digital-experience analytics.

According to the release, the purchase represents ContentSquare’s largest acquisition to date, and will allow the company, which was founded in 2013, to deliver “an all-in-one analytics platform that will serve as an advanced alternative to traditional analytics.”

Please Read These Important Legal Notices & Disclosures

The information and material presented in this article is provided for your informational purposes only and does not constitute an offer by Forge Europe GmbH or Forge Europe UK Limited or any of its affiliates to sell, or a solicitation of an offer to buy any securities and may not be used or relied upon in connection with any offer or sale of securities.

If you are a resident or a company registered within Germany this content is for marketing purposes only and on behalf of Forge Europe GmbH of Unter den Linden 38, 10117 Berlin, Germany (registered in the District Court Berlin (Charlottenburg) HRB 240763). Forge Europe GmbH is a tied agent in accordance with §3 (2) WpIG and provides investment brokerage, pursuant to §2 (2) Nr. 3 WpIG, exclusively in the name, on the account and under the liability of Effecta GmbH, Florstadt. If you are resident or a company registered within the United Kingdom or Gibraltar this content is for general marketing purposes only and not a financial promotion on behalf of Forge Europe UK Limited of 10 York Road, London, SE1 7ND, England (registered in England and Wales with company number 14877431). Forge Europe UK Ltd is an Appointed Representative of Sapeno Partners LLP which is authorised and regulated by the Financial Conduct Authority.

Forge Europe GmbH and, its wholly owned subsidiary, Forge Europe UK Limited (together “Forge Europe”) accept liability to a client as set out in the individual agreement entered into with the client. All other liability to any client is expressly excluded to the fullest extent permitted by applicable laws and regulations. Each Forge Europe company expressly excludes all liability to the fullest extent permitted by applicable laws and regulations to any person who is not a client. You will only be a client if you have entered into a written client agreement with the relevant Forge Europe company. To the extent information about or defining specific terms is provided herein, Forge Europe makes no representations as to its accuracy and has no duty to update such information. Such information is based on experience Forge Europe and its affiliates and the meanings and connotations of terms as Forge Europe typically uses and interprets them. Others may construe such terms differently, and you should do your own research and consult with financial, legal and tax professionals regarding any such concepts included herein.

This article does not constitute an offer to provide investment advice or service. Forge Europe does not (1) advise any member on the merits or prudence of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative, involving a high degree of risk, and investors should be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks and investors should conduct their own, independent due diligence regarding the investment, including obtaining additional information about the company, opinions, financial projections and legal or investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. Past performance Is not indicative of future results.

This material may be distributed to, or directed at, only the following persons: (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “FP Order”), (ii) high-net-worth entities falling within Article 49(2) of the FP Order, and (iii) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “FPO Relevant Persons”). Persons who are not FPO Relevant Persons must not act on or rely on this material or any of its contents. Any investment or investment activity to which this material relates is available only to FPO Relevant Persons and will be engaged in only with FPO Relevant Persons. Recipients must not distribute, publish, reproduce, or disclose this material, in whole or in part, to any other person. This content is for the sole use of the intended recipient(s). Any unauthorized review, use, disclosure or distribution is prohibited.